EN | TR
E-ISSN: 3061-9947
Retrospective analysis of patients diagnosed with multiple myeloma: A single center experience
PDF
Cite
Share
Request
Original Article
VOLUME: 52 ISSUE: 2
P: 213-220
2019

Retrospective analysis of patients diagnosed with multiple myeloma: A single center experience

Acta Haematol Oncol Turc 2019;52(2):213-220
DOI: 10.5505/aot.2019.24582
Melih Simsek 1
Pinar Tarkun 2
Abdullah Hacıhanefioğlu 2
1. Yozgat City Hospital, Yozgat
2. Kocaeli University, Faculty Of Medicine, Department Of Internal Medicine, Department Of Hematology, Kocaeli
3.
No information available.
No information available
Received Date: 2018-10-18T21:32:39
Accepted Date: 2019-08-30T09:53:21
PDF
Cite
Share
Request

Abstract

INTRODUCTION

Multiple myeloma is a hematological malignancy which is proceeding with the uncontrolled proliferation of plasma cells. Patients should be determined more definitely and treatments should be standardized to modify various treatment options in multiple myeloma. The aim of this study is to analyse the responses to treatments and the association between clinical features and treatments of multiple myeloma patients.

METHODS

The clinical and laboratuary findings with survival and treatment response data of 151 multiple myeloma patients who have been followed between 2000-2011 were analysed retrospectively.

RESULTS

The most prefered treatments were melphalan-prednisolone (45%), vincristin-adriamicin-dexamethasone (21,3%) and vincristin-adriamicin-dexamethasone followed by bortezomib (10%). Death was observed in 22,35% of the patients that remission was established at least for once. This rate was 77,35% in the patients that remission could not be established (p=0,000). Remission rate was significantly decreased (p=0.008) and death rate was significantly increased (p=0.000) in stage III disease compared with lower stages. Autologous stem cell transplantation, significantly decreased the relapse rate (p=0.009) and death risk (p=0.001). When the treatment protocols were analyzed, remission rate was 57,9% with vincristin-adriamicin-dexamethasone followed by bortezomib, 33,3% with melphalan-prednisolone, 29,2% with bortezomib, 9,4% with thalidomide, 23,8% with lenalidomide and 25,7% with vincristin-adriamicin-dexamethasone, respectively. Maintenance therapy with low dose lenalidomide was administered to 23 of 101 patients that remission was maintained. Autologous stem cell transplantation was administered to 21 patients that remission was obtained. Recurrence rate was significantly lower in patients who were received low dose lenalidomide maintenance therapy (p=0.002) (OR: 12,52).

DISCUSSION AND CONCLUSION

The highest remission rates were obtained with vincristin-adriamicin-dexamethasone followed by bortezomib. Lower recurrence and death rates were established with autologous stem cell transplantation. Recurrence and death rates were found lower in patients that received low dose lenalidomide maintenance therapy.